Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc7.5 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing’s disease: findings from the phase III LINC 3 study

Pivonello Rosario , Fleseriu Maria , Akira Shimatsu , Newell-Price John , Auchus Richard , Feelders Richard , Pedroncelli Alberto , Piacentini Andrea , Biller Beverly MK

Background: Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat therapy, a potent oral 11β-hydroxylase inhibitor, rapidly normalised mean urinary free cortisol (mUFC) in most patients with CD and sustained control of mUFC over a median treatment period of 130 weeks (W). Here we describe concomitant improvements in physical manifestation...

ea0090ep801 | Pituitary and Neuroendocrinology | ECE2023

An Open-Label Extension Study to Evaluate the Safety of Long-term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

Badiu Corin , Mariash Cary N. , Kautzky-Willer Alexandra , Shlomai Gadi , Aresta Carmen , Pivonello Rosario , Dischinger Ulrich , Bancos Irina , Dobri Georgiana , Hamrahian Amir , Auchus Richard , Feelders Richard , Recasens Monica , Chmiel-Perzynska Iwona , Pearson Emily , Moraitis Andreas G. , Araque Katherine

Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...

ea0041s13.1 | Management of Cushing's syndrome | ECE2016

New developments in the medical treatment of Cushing’s disease

Feelders Richard

Cushing’s disease (CD), caused by a corticotroph pituitary adenoma, is associated with multi-system morbidity and when untreated or suboptimally treated with an increased mortality. Transsphenoidal adenomectomy is the first choice of treatment for CD. Medical treatment is an option in patients in whom surgery is not successful or not feasible. Medical therapy for CD can be classified into pituitary-directed drugs, adrenal-blocking drugs and glucocorticoid receptor antagon...

ea0029en2.1 | (1) | ICEECE2012

Diagnosis and management of Cushing’s syndrome

Feelders Richard

Cushing’s syndrome (CS) is characterized by chronic overproduction of cortisol resulting in significant morbidity and, when untreated, an increased mortality. CS is divided into adrenocorticotropin (ACTH)-dependent CS and ACTH-independent CS. ACTH-dependent CS, the majority of cases, can be caused by a corticotroph pituitary adenoma and, more rarely, by ectopic ACTH production. ACTH-independent CS is usually caused by an unilateral adrenal adenoma and less frequent by an ...

ea0099p340 | Pituitary and Neuroendocrinology | ECE2024

Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing’s disease: A pooled analysis of LINC 3 and LINC 4

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Gadelha Monica , Auchus Richard , Feelders Richard , Lacroix Andre , Akira Shimatsu , Witek Przemysław , Bex Marie , Piacentini Andrea , Pedroncelli Alberto , M.K. Biller Beverly

Introduction: Diabetes mellitus (DM) and hypertension are common comorbidities that pose significant clinical burden in Cushing’s syndrome patients and may be improved by normalising cortisol. In two Phase III trials (LINC3 [NCT02180217]; LINC4 [NCT02697734]), osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided reductions in cortisol and improved clinical manifestations of hypercortisolism in most Cushing’s disease (CD) patients. Here, we describe ch...

ea0099p231 | Adrenal and Cardiovascular Endocrinology | ECE2024

3D printed, personalized cortisol for cortisol deficiencies

Ayyoubi Sejad , Feelders Richard , Ruijgrok Liesbeth

Introduction: The current standard of care (SOC) for adrenal insufficiency (AI) is suboptimal due to fluctuating cortisol plasma concentrations. The sub- and supraphysiological cortisol levels, combined with the multi day tablet intake, are associated with negative health outcomes and a poor quality of life. Furthermore, there is a high interindividual difference in the cortisol need, demanding a personalized approach. 3D printing (3DP) has gained momentum within the pharmaceu...

ea0070aep589 | Pituitary and Neuroendocrinology | ECE2020

The cushing’s collaborative patient survey results

Valassi Elena , Tabarin Antoine , Chiodini Iacopo , Feelders Richard , Andela Cornelie

Background: Early diagnosis of Cushing’s syndrome and initiation of effective treatment are essential to limit long-term morbidity and early mortality. However, diagnosis is often delayed due to the non-specificity of symptoms, or because symptoms are not recognised by physicians, leading to more complex treatment needs and a worsening of patient quality of life. A survey was conducted to better understand the patient experience of Cushing’s syndrome and the true b...

ea0081p5 | Adrenal and Cardiovascular Endocrinology | ECE2022

Group education programme for patients with adrenal insufficiency: evaluation based on patients experiences

Davidse Kirsten , Geilvoet Wanda , Brinkman Lotte , van Eck J.P. , Feelders Richard , Van der Lely Aart Jan

Introduction: Adequate hormone replacement therapy in adrenal insufficiency is essential. Patients should have basic knowledge about their condition and what to do in situations which could trigger an adrenal crisis. Education on how and when hydrocortisone replacement therapy should be adjusted as well as instruction and practice an emergency injection are considered important measures to prevent an adrenal crisis. A standardized nurse-led group-based education programme (GEP...

ea0049ep182 | Endocrine tumours and neoplasia | ECE2017

Effects of ketoconazole on ACTH-producing and non ACTH-producing neuroendocrine tumor cells

Herrera-Martinez Aura D , Feelders Richard , Castano Justo , Dogan Fadime , Koetsveld Peter van , Hofland Leo

Prolonged spontaneous remission of hypercortisolemia in ectopic ACTH syndrome after long-term treatment with steroidogenesis inhibitors has been described. Direct drug effect on the adrenal glands, effects on tumoral ACTH secretion and/or POMC gene expression have been suggested. Medical treatment could be used for symptoms, but also for disease control.Materials and methods: In human BON-1 and DMS-79 cells, we have evaluated the effects of keto...

ea0049ep933 | Pituitary - Basic | ECE2017

Acquired temozolomide resistance in ACTH-secreting pituitary tumour cells

Silva Ticiana , Van Koetsveld Peter , Dogan Fadime , Feelders Richard , Hofland Leo

Introduction: Temozolomide (TMZ) treatment has been used for aggressive pituitary tumours with positive results, but has proven ineffective in controlling tumour regrowth in cases of disease recurrence. TMZ resistance has been linked to the expression of O6-methyl-guanine-DNA-methyltransferase (MGMT) protein and mismatch repair components (MMR). In the present study, we describe the development of an in vitro model of acquired resistance to TMZ and the mechanisms invo...